EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Treatment of refractory solar urticaria: could dupilumab fill the current gap?

Francisco José Navarro-Triviño, Alvaro Prados-Carmona, José Aguilera, Maria Victoria de Gálvez, Ricardo Ruiz-Villaverde

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023

DOI: 10.1111/ddg.15025 ↗

Kurz gefasst

Leserbrief in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2023. Verfasst von Francisco José Navarro-Triviño und 4 weiteren Autor:innen. Beteiligte Einrichtung: Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada, Spain. Hauptthemen laut MEDLINE: Urticaria, Solar, Urticaria. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dear Editors, there are still unmet therapeutical needs regarding chronic inducible urticaria (CIndU). Nevertheless, the regulatory situation that Can P. K. et al.1 reported last year remains, and we are still lacking medications covering this indication in their technical data sheets. A 43-year-old white Caucasian male, with no relevant family or personal history, was referred to us for an intermittent skin rash for 8 years. The patient’s photographic documentation showed an erythematous rashwith sharply demarcated borders, persistently limited to sun-exposed areas (Figure 1). Angioedema was never present. The rash typically occurred in the first twenty to forty minutes after sun exposure, was accompanied by intense itch, and resolved within the first sixty minutes. The patient reported no improvement despite previous treatments with antihistamines (cetirizine, rupatadine, among others), sometimes quadrupling the recommended dose. No positive response was achieved following six months of treatment with 300mg subcutaneous omalizumab every 4weeks, nor after a higher dosing to 450 mg every 4 weeks for three more months, and therefore this treatment was discontinued. Porphyrias, autoantibodies, and KIT gene mutation screenings (high serum tryptase levels were repeatedly found, 18.0 and 20.3 μg/l [normal laboratory range 0–11.4 μg/l] were also negative, ruling out possible systemicmastocytosis. The patient was then referred to the photobiology unit (Dermatological Photobiology Laboratory of the University of Málaga), where UVA photosensitivity was demonstrated upon phototesting (minimal erythemal dose was low, 18

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urticaria, SolarUrticariaHumansAntibodies, Monoclonal, Humanized

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Contact Eczema and Immunoallergic Diseases, Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
  • Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
  • Dermatological Photobiology and Cutaneous Oncology Unit, Department of Dermatology and Medicine, University of Malaga, Malaga, Spain.

Zitieren

APA

Navarro-Triviño, F. J., Prados-Carmona, A., Aguilera, J., de Gálvez, M. V., & Ruiz-Villaverde, R. (2023). Treatment of refractory solar urticaria: could dupilumab fill the current gap?. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15025

Vancouver

Navarro-Triviño FJ, Prados-Carmona A, Aguilera J, de Gálvez MV, Ruiz-Villaverde R. Treatment of refractory solar urticaria: could dupilumab fill the current gap?. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023. doi:10.1111/ddg.15025

BibTeX
@article{NavarroTrivio2023,
  author = {Navarro-Triviño, Francisco José and Prados-Carmona, Alvaro and Aguilera, José and de Gálvez, Maria Victoria and Ruiz-Villaverde, Ricardo},
  title = {Treatment of refractory solar urticaria: could dupilumab fill the current gap?},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2023},
  doi = {10.1111/ddg.15025}
}
Kostenlos starten →